Acurx plans ibezapolstat rCDI pilot trial; executives and directors take pay cuts
Acurx Pharmaceuticals said executive officers voluntarily agreed to base salary reductions of 10%, effective April 1, 2026, and the board approved a 10% cut to the cash components of non-employee director pay. The company also announced a pilot trial of its lead antibiotic candidate, ibezapolstat, in patients with multiply-recurrent C. difficile infection, with trial start-up later in March and first-patient enrollment expected in the fourth quarter of 2026, subject to appropriate funding.
Key points
- CEO David P. Luci and Executive Chairman Robert J. DeLuccia will each have a $495,000 annual base salary, and CFO Robert G. Shawah will have $360,000, effective April 1, 2026
- Director cash compensation, including board, chair and committee retainers, will be reduced by 10% effective April 1, 2026
- The open-label pilot trial will enroll up to 20 patients who have had at least two recurrences within the past 12 months; data will inform a planned Phase 3 trial
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.